Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to -$2.0 million.

  • Protagonist Therapeutics' Free Cash Flow rose 92.93% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 72.21%. This contributed to the annual value of $182.8 million for FY2024, which is 358.02% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Free Cash Flow is -$2.0 million, which was up 93.16% from -$29.6 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Free Cash Flow high stood at $268.6 million for Q2 2024, and its period low was -$37.9 million during Q1 2022.
  • Its 3-year average for Free Cash Flow is $18.7 million, with a median of -$27.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Protagonist Therapeutics' Free Cash Flow was 1,117.04% (2024), while the steepest drop was 274.06% (2024).
  • Over the past 5 years, Protagonist Therapeutics' Free Cash Flow (Quarterly) stood at -$27.1 million in 2021, then dropped by 16.84% to -$31.7 million in 2022, then skyrocketed by 153.43% to $16.9 million in 2023, then plummeted by 274.06% to -$29.5 million in 2024, then surged by 92.93% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$29.6 million for Q2 2025, and $124.8 million during Q1 2025.